CSOP FTSE East-West Equity Select ETF(03441.HK) rose 0.51% to HKD 11.760
Newtimespace News, as of 09:34 on May 6, CSOP FTSE East-West Equity Select ETF(03441.HK) was quoted at HKD 11.760, up 0.51%. The ETF opened at HKD 11.800, with a high of HKD 11.800 and a low of HKD 11.740. The latest trading volume was 77,500 units, with a turnover of HKD 911,500, and a turnover rate of 0.11%. The latest NAV per unit is HKD 11.791, with a premium rate of -0.25%. The asset size is approximately HKD 849 million, and the total issuance is 72.00 million units.
CSOP FTSE East-West Equity Select ETF(03441.HK) is a cross-border ETF whose investment scope covers both the Hong Kong and U.S. markets. The fund aims to capture the growth opportunities in both Eastern and Western hemisphere markets through diversified investments in quality assets across different markets, providing investors with a tool for diversified asset allocation. As a cross-border ETF, its NAV performance is subject to the dual influence of both the Hong Kong and U.S. stock markets, carrying relatively high geopolitical and market volatility risks.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
- SCIENTECH (02291.HK): Acquires 54.2384% Equity of Shanghai Minwei Biotechnology for RMB 1.088 Billion, Constituting Major and Connected Transaction
- CHINAHONGQIAO (01378.HK): Revises Annual Caps under Industrial Products Purchase Agreement, 2027 Cap Raised to RMB 26.24 Million